Insulin-like growth factor binding proteins show distinct patterns of expression in the rat uterus

An intrinsic insulin-like growth factor (IGF) system, complete with IGF ligands, receptors, and biological responses, is present in the rat uterus, where it is thought to regulate uterine homeostasis by autocrine/paracrine mechanisms. It is known that IGF binding proteins (IGFBP) modulate IGF-I and IGF-II action, but very little information is available concerning their cellular localization in the uterus. Therefore, we have employed in situ hybridization to localize IGFBP-1, -2, -3, -4, -5, and -6 mRNAs in the adult rat uterus during the estrous cycle. IGFBP-1 was undetectable in all uteri examined. IGFBP-2 mRNA was localized only in the luminal epithelium of the endometrium. It was abundant during proestrus (P1000 h, P2000 h) and early estrus (E0200 h), but was relatively low at other stages of the cycle. IGFBP-3 mRNA was localized to the stroma cells juxtaposed to the endometrium. A weak signal was detected on estrus morning (E0200 h, E1000 h), but high levels of IGFBP-3 mRNA were observed in the stroma cells on Day 12 of pregnancy. IGFBP-4 mRNA was localized only in the luminal epithelium of the endometrium. It was moderately abundant at diestrus I and II, but the signal was very low or absent at other times in the cycle. IGFBP-5 mRNA was localized in the circular and longitudinal muscle layers of the myometrium. The IGFBP-5 hybridization signal was maximal at diestrus, weak on proestrus, and moderate during estrus. IGFBP-6 mRNA was also expressed in the myometrium. The signal was strong on estrus morning (E0200 h and E1000 h) and low or absent at other times in the cycle. These results provide the first direct evidence that the genes encoding the six IGFBP are expressed in a tissue-specific manner in the adult rat uterus. Equally important, the levels of the mRNA for each IGFBP appear to change throughout the estrous cycle, but not in a parallel fashion. These results support the hypothesis that inducible and tissue-specific expression of IGFBP-2 to -6 may be involved in modulating the activity of the IGF ligands during the proliferative and secretory phases of the uterine cycle.

Hormonal regulation of insulin-like growth factor II and insulin-like growth factor binding protein expression by breast cancer cells in vivo: evidence for stromal epithelial interactions

Insulin-like growth factors (IGFs) I and II are potent mitogens for breast cancer cells. Their proliferative activity is likely to be influenced by their binding proteins (IGFBPs), a family of newly identified proteins. We report here on the in vivo hormonal regulation of mRNAs for IGF-II and IGFBPs in the N-nitrosomethylurea-induced rat mammary tumor, a well-established model of hormone-responsive mammary cancer. IGF-II mRNA levels tended to decrease in regressing tumors following ovariectomy, and they markedly increased upon reactivation of tumor growth with hormone repletion. Ovariectomy induced a drastic increase in IG-FBP-6 mRNA which was reversible with hormone repletion. Similar but more modest changes were observed with IGFBP-2 mRNA. In contrast, IGFBP-3 and IGFBP-4 mRNAs tended to decrease with ovariectomy and increase with hormone repletion. These latter effects, however, were modest, variable, and not statistically significant. In situ hybridization analysis revealed that IGF-II, IGFBP-5, and IGFBP-6 mRNAs were localized in the stromal component of the tumor, whereas IGFBP-2 mRNA was expressed by epithelial cells. We conclude that hormonal regulation of IGFBP expression is heterogeneous, thus suggesting divergent biological functions for these peptides. Our data also emphasize the importance of potential stromal-epithelial interactions in the control of breast cancer cell proliferation by IGFs.

Porcine ovarian granulosa cells secrete insulin-like growth factor-binding proteins-4 and -5 and express their messenger ribonucleic acids: regulation by follicle-stimulating hormone and insulin-like growth factor-1

Using ligand blotting, Western immunoblotting, and Northern analysis, we have characterized the insulin-like growth factor (IGF)-binding proteins (IGFBPs) produced by cultures of porcine granulosa cells. Ligand blot analysis of conditioned medium from untreated cultures of moderately differentiated granulosa cells (MDGCs; from 4-6-mm follicles) revealed mainly IGF-binding activity associated with IGFBP-2 (34 kDa) and IGFBP-3 (40/44-kDa doublet), which have previously been identified and characterized. In addition, these cultures secreted 30- and 22-kDa forms under some circumstances. The identification and regulation of these IGFBPs of lower molecular mass were the focus of the current studies. Treatment of these MDGCs with IGF-I dramatically stimulated the production (to a detectable level) of a 30-kDa IGFBP that was identified by immunoblotting with antiserum to IGFBP-5 but not antisera to IGFBP-1, -2, -3, -4, or -6. Production of IGFBP-5 was attenuated by concurrent treatment with FSH. IGFBP-5 mRNA in these cultures was correspondingly stimulated by IGF-I but unaffected by FSH. FSH increased the level of a minor 22-kDa IGFBP. Messenger RNAs for IGFBP-1, -4, and -6 were also examined but only IGFBP-4 mRNA was detectable, suggesting that the 22-kDa band was IGFBP-4. These results were compared to those in cultures of immature granulosa cells from 1-3-mm follicles, in which 22- and 30-kDa IGFBPs were readily detectable. An antiserum to IGFBP-4 precipitated the 22- and 30-kDa bands whereas deglycosylation shifted the 30-kDa IGFBP to 22 kDa, suggesting that both these bands represent glycosylation variants of IGFBP-4.(ABSTRACT TRUNCATED AT 250 WORDS)

Follicle-stimulating hormone regulation of AP-1: inhibition of c-jun and stimulation of jun-B gene transcription in the rat Sertoli cell

The proto-oncogenes c-fos and c-jun and the related jun-B encode the components of transcription factor, AP-1, a heterodimeric DNA-binding protein that mediates hormone and growth factor-regulated gene expression. In the rat Sertoli cell, FSH rapidly inhibited c-jun gene expression while it stimulated c-fos and jun-B as well as the expression of the more slowly responding, tissue plasminogen activator (tPA) and inhibin alpha-subunit. These early effects of FSH were not inhibited by cycloheximide. Nuclear run-off analyses demonstrated that the FSH-dependent decline in c-jun and increases in c-fos, jun-B, tPA and inhibin alpha-subunit mRNAs were regulated at the transcriptional level. The rates of degradation of c-fos, c-jun and jun-B mRNAs were unaffected by FSH while tPA and inhibin alpha-subunit mRNAs were stabilized. After 8 h of FSH treatment, the transcription of all five genes returned to basal rates. These data demonstrate immediate-early regulation by FSH of the expression of genes encoding components of the transcription factor, AP-1.

Extrapituitary actions of gonadotropin-releasing hormone: stimulation of insulin-like growth factor-binding protein-4 and atresia

To understand how the intrinsic GnRH system functions in the ovary, we tested the effects of GnRH agonist (GnRH-a) on insulin-like growth factor-binding protein-4 (IGFBP-4) production, a novel marker of atresia. We also tested the ability of GnRH-a to stimulate atresia in vivo. When rat granulosa cells were cultured in defined medium for 2 days (controls), relatively large amounts of the 24,000 relative molecular mass IGFBP-4 accumulated in the medium. FSH (100 ng/ml) inhibited control IGFBP-4 protein levels and stimulated IGFBP-4 protease activity. GnRH-a increased (up to 4-fold) IGFBP-4 accumulation in the medium (ED50 = 1 x 10(-10) M), and the effect was blocked by a GnRH antagonist. Neither GnRH-a nor its antagonist had a detectable effect on protease activity. In coincubation experiments, GnRH-a effectively inhibited (ED50 = 3 x 10(-11) M) the FSH responses, and the effect of GnRH-a was blocked by GnRH antagonist. A 6-day time-course experiment showed that IGFBP-4 accumulation in control cultures remained constant for 2 and 4 days, after which it was undetectable. FSH (100 ng/ml) produced no measurable IGFBP-4 over the 6-day time course. The levels of IGFBP-4 increased markedly during the first 2 days of GnRH-a treatment, but were not significantly different from control levels on days 4 and 6. Similar results were obtained when cells were treated with FSH plus GnRH-a. Treating immature hypophysectomized estrogen-primed rats with GnRH-a in vivo caused a rapid and dramatic decrease (average, 60%) in the mitotic index of the granulosa cells of all preantral follicles (healthy and atretic) and increased pyknosis. These results demonstrate that 1) GnRH-a stimulates the expression of IGFBP-4 protein in rat granulosa cells in vitro; 2) GnRH-a abolishes the ability of FSH to inhibit IGFBP-4 expression and induce IGFBP-4 protease activity; and 3) GnRH-a stimulates atresia in preantral follicles in vivo. These results support the hypothesis that autocrine/paracrine secretion of ovarian GnRH might cause atresia by mechanisms involving increased IGFBP-4 synthesis.

Insulin-like growth factor-binding protein-2: the effect of human chorionic gonadotropin on its gene regulation and protein secretion and its biological effects in rat Leydig cells

Human CG (hCG) and insulin-like growth factor-I (IGF-I) have synergistic effects on Leydig cell function. Leydig cells express high affinity IGF-I receptors. The number of IGF-I receptors and IGF-I receptor mRNA levels can be up-regulated by hCG. The most abundant mRNA species of the IGF binding proteins (IGFBPs) in rat Leydig cells is IGFBP-2. In the present study, we investigated the effect of hCG on IGFBP-2 transcription, mRNA accumulation, and protein production/secretion. Biological effects of IGFBP-2 on Leydig cells were also examined. Rat Leydig cells were purified from testes using centrifugal elutriation followed by Percoll gradient centrifugation. Cells were cultured for 24 h and then treated with or without hCG (10 ng/ml) for 6 h. The expression of IGFBP-2 mRNA was decreased by hCG in a dose-dependent manner, and at a concentration of 10 ng/ml the expression of IGFBP-2 mRNA was reduced by 50%. As early as 2 h after the addition of hCG, there was a significant decrease in IGFBP-2 mRNA accumulation. To evaluate the mechanism(s) responsible for decreased IGFBP-2 gene expression by hCG, the effect of hCG on the rate of transcription and stability of the mRNA was determined. Human CG (10 ng/ml) reduced the IGFBP-2 transcription rate by 32%/h in comparison with the control, while the half-life (t1/2) of mRNA remained unaltered (hCG-treated cells, 0.58 h; control cells, 0.51 h). IGFBP-2 with a molecular size of 33 kilodaltons was detected as a major band in the Western ligand blot.(ABSTRACT TRUNCATED AT 250 WORDS)

Insulin-like growth factor binding protein-3 gene expression is restricted to involuting corpora lutea in rat ovaries

There is evidence that insulin-like growth factor binding protein-3 (IGFBP-3) is a part of the intrinsic IGF system in rat CL. Here, we examined when during luteogenesis the IGFBP-3 gene is expressed. IGFBP-3 messenger RNA (mRNA) was characterized by Northern analysis and in situ hybridization techniques. Animals were selected at proestrus (P 1000 h and P 2000 h), estrus (E 0200 h and E 1000 h), diestrus I (DI 1100 h), and diestrus II (DII 1100 h), and in pregnancy (day 12, before luteolysis and day 21, during luteolysis). A single 2.6 kilobase IGFBP-3 transcript was identified at each stage of the estrous cycle; however, the amounts of message varied markedly, being most abundant at P 1000 h, least abundant at P 2000 h, E 0200 h, E 1000 h, and DI, and then more abundant at DII. Corroborating our earlier report, IGFBP-3 mRNA was limited solely to corpora lutea (CL). Newly-formed CL-I at E 0200 h and E 1000 h revealed no IGFBP-3 hybridization. This is the period of early luteinization when cells undergo hypertrophy and capillaries and lymphatics penetrate the granulosa lutein layer. At DI 1100 h, a few cells (12.2 +/- 3.4%) near the central cavity of the CL-I showed a positive hybridization signal for IGFBP-3; this period is commensurate with active luteinization when the vascular tissue develops a distinctly sinusoidal character and progesterone secretion by CL-I increases. At DII 1100 h, more cells in the central area were positive for IGFBP-3 (55.2 +/- 6.4%); this is the period of active luteolysis when P4 secretion has fallen to basal levels. At P 1000 h, a positive IGFBP-3 hybridization signal was detected in most CL-I cells (85.3 +/- 2.8%), and the signal was particularly intense in subtypes of endothelial cells lining venous sinusoids and/or lymphatics and some perivascular cells; this is the period when patches of pyknotic cells appear in the central area of CL-I. At P 2000 h, 45.9 +/- 1.6% of the CL-I cells showed a positive signal; however, the intensity of the signal was much weaker when compared to P 1000 h. During the next cycle, the CL-I become the CL of the second generation (CL-II), which show increased necrosis. Between estrus and diestrus II of the next cycle, a large number of the CL-II cells (approximately 75%) were positive for IGFBP-3 and the signal was very strong in some groups of cells.(ABSTRACT TRUNCATED AT 400 WORDS)

Molecular heterogeneity of follistatin, an activin-binding protein. Higher affinity of the carboxyl-terminal truncated forms for heparan sulfate proteoglycans on the ovarian granulosa cell

Follistatin (FS), an activin-binding protein, is a monomer derived from two polypeptide core sequences of 315 (FS-315) and 288 (FS-288) amino acids originated from alternatively spliced mRNA. To define the structural heterogeneity of native FS, we purified six molecular forms of FS from porcine ovaries. Protein chemical analysis revealed that the structural differences among the six isoforms were caused by truncation of the carboxyl-terminal region and/or the presence of carbohydrate chains, resulting in the formation of FS-315, FS-288, and FS composed of 303 amino acids (FS-303) in various forms of glycosylation on the two potential Asn-linked glycosylation sites. The majority of FS isolated from porcine ovaries was FS-303, which may have been derived from FS-315 by proteolytic cleavage of the 12 COOH-terminal amino acids. All six molecular species have almost the same activin binding activity (Kd = 540-680 pM). By contrast, the COOH-terminal truncated form, FS-288, showed much higher affinity for the rat granulosa cell surface than FS-303, whereas FS-315 had no affinity. FS-288 bound to heparan sulfate-Sepharose CL-4B, but FS-315 did not, suggesting that the truncated forms of FS bind to heparan sulfate proteoglycans on the cell. COS cells transfected with the FS-288 DNA expressed the FS-288 protein, which adhered to the cell surface, but cells transfected with the FS-315 DNA secreted the expressed protein into the medium, which did not bind to the cell surface. In rat anterior pituitary culture, FS-288 (ED50 = 2 ng/ml) was more potent in suppressing follicle-stimulating hormone release than FS-303 (ED50 = 10 ng/ml) and FS-315 (ED50 = 20 ng/ml). These results suggest that cell-associated FS traps activin more tightly in the matrix, thereby more effectively blocking the activity of activin on heparan sulfate proteoglycans of the cell surface and that cell-associated FS plays an important role in controlling the various actions of activin in a paracrine or autocrine manner.

Differential control of activin, inhibin and follistatin proteins in cultured rat granulosa cells

Follistatin, activin and inhibin proteins are produced by granulosa cells, but the mechanisms controlling their production remain unclear. Here, we examined how the protein kinase A (PKA) and protein kinase C (PKC) pathways act and interact to regulate production of these proteins. Granulosa cells from immature rats were cultured with activators of the PKA pathway (100 ng/ml FSH, 10 microM forskolin) and/or activators of the PKC pathway (100 nM GnRH agonist, 100nM 2-0-tetradecanoyl-phorbol-13-acetate, TPA). Conditioned media were assayed for inhibin and activin by ligand blotting using recombinant human 125I-follistatin and for follistatin by double ligand blotting using cold activin plus 125I-follistatin. FSH and forskolin stimulated inhibin but not activin production. In contrast, GnRH and TPA stimulated activin, and to a lesser degree, inhibin production; significantly, this is the first demonstration of activin dimer production by granulosa cells. Activators of the PKA pathway antagonized the actions of PKC effectors and vice versa. All agents increased follistatin protein production, and the PKA and PKC activators interacted to generate further increases in follistatin production. These results show that the FSH-PKA signalling pathway favors formation of alpha beta inhibin dimers while the GnRH-PKC pathway favors formation of beta-subunit activin dimers. Both pathways act to increase follistatin protein production.

Expression and regulation of insulin-like growth factor-binding protein-1, -2, -3, and -4 messenger ribonucleic acids in purified rat Leydig cells and their biological effects

The actions of insulin-like growth factor-I (IGF-I) are modified by binding proteins [IGF-binding proteins (IGFBPs)]. Previously, we reported that IGF-I enhances Leydig cell steroidogenesis and that IGF-I mRNA is expressed in Leydig cells. In the present study, we evaluated the expression and regulation of IGFBP-1, -2, -3, and -4 in purified rat Leydig cells and their biological effects. We found that none of the testicular crude interstitial cells, purified Leydig cells, or seminiferous tubules expressed IGFBP-1 mRNA. This indicated that IGFBP-1 mRNA is not expressed in the testis in detectable amounts. In contrast, large amounts of IGFBP-2 with a size of 1.8 kilobases (kb) were expressed in purified Leydig cells, and lesser amounts in crude interstitial cells. Small amounts of IGFBP-2 mRNA were expressed in seminiferous tubules, but none could be detected in liver. IGFBP-3 mRNA was predominantly expressed in purified Leydig cells, crude interstitial cells, and liver, while appreciable amounts were not found in seminiferous tubules. Liver had the highest amounts of IGFBP-4 mRNA, whereas purified Leydig cells and crude interstitial cells had lesser amounts. We next evaluated the pituitary dependency of IGFBP mRNAs in Leydig cells. Purified Leydig cells were isolated from 50-day-old rats 5 days after hypophysectomy. IGFBP-2, -3, and -4 mRNA levels in Leydig cells decreased 22%, 80%, and more than 90%, respectively, after hypophysectomy. In the liver, however, IGFBP-2 mRNA levels increased, and IGFBP-3 mRNA levels decreased, while IGFBP-4 remained unchanged. As expected, hypophysectomy caused decrements in large (7.0- to 7.5-kb; a 75% reduction) and small (0.8- to 1.2-kb; a 90% reduction) IGF-I mRNA levels in Leydig cells. Hypophysectomy also reduced IGF-I mRNA expression in liver. Finally, the effects of IGFBP-2, -3, and -4 on Leydig cell testosterone formation were investigated. hCG in a concentration of 10 ng/ml increased testosterone formation from 0.6 +/- 0.01 to 27.4 +/- 1.01 ng/10(6) cells.h. In the presence of IGF-I (10 ng/ml), testosterone formation was further increased to 58.6 +/- 1.6 ng/10(6) cells.h (P < 0.01). IGFBP-3 (0.1, 1, and 2.5 pmol/ml) caused a dose-dependent inhibition of IGF-I- plus hCG-induced testosterone formation. IGFBP-3 in a concentration of 2.5 pmol/ml completely neutralized the effects of IGF-I on Leydig cell steroidogenesis. IGFBP-4 had a lesser effect, while IGFBP-2 had no effect on IGF-I- plus hCG-induced testosterone formation.(ABSTRACT TRUNCATED AT 400 WORDS)

Effects of estrous cycle stage and pregnancy on follistatin gene expression and immunoreactivity in rat reproductive tissues: progesterone is implicated in regulating uterine gene expression

Follistatin, a monomeric protein originally isolated from ovarian follicular fluid, is now believed to be a major local regulator of the multifaceted actions of activin by virtue of its activin-binding properties. In view of the ability of follistatin to stimulate progesterone production from granulosa cells and its presence in newly formed corpora lutea, the following study was conducted to determine the effects of cycle stage and pregnancy on follistatin gene expression and immunoreactivity in the rat ovary and uterus with the intent of gaining additional insights into the regulation of follistatin in these tissues. Decidua and placentas were also examined on days 15, 18, and 21 of pregnancy. Follistatin messenger RNA (mRNA) levels were quantified using a sensitive solution hybridization-RNase protection assay and values normalized to the amount of cyclophilin mRNA present in each sample. Levels of follistatin-like immunoreactivity (FLI) in serum and tissues were estimated using a homologous porcine follistatin RIA. Follistatin message levels in the ovary increased between proestrus and estrus with a return to proestrous values on both days of diestrus. In the nonpregnant uterus, mRNA levels on proestrus were similar to levels measured in uteri taken from hypophysectomized or ovariectomized rats. Interestingly, follistatin gene expression increased almost 3-fold between proestrus and estrus. An additional experiment demonstrated that this increase could be abated by treatment of proestrous rats with pentobarbital which blocks preovulatory rises in serum progesterone levels and could be restored by administration of progesterone to pentobarbital-treated proestrous rats. In pregnant rats, ovarian follistatin message levels on days 3 and 6 of pregnancy were identical to levels observed on day 2 of diestrus. However, an abrupt 4-fold increase in ovarian mRNA levels occurred between days 6 and 9 with a further 58% increase occurring by day 12. This marked increase in message levels was unaccompanied by changes in ovarian FLI levels. A precipitous decrease in transcript levels accompanied by a decline in FLI levels then followed with ovarian gene expression on days 15 through 21 being slightly higher than expression during the initial stages of gestation. Expression of the gene in the decidua and placenta did not vary between days 15 and 21 of pregnancy. Levels of FLI in serum also were invariant during the cycle and pregnancy.(ABSTRACT TRUNCATED AT 400 WORDS)

Structural characterization of the rat insulin-like growth factor binding protein-6 gene

Recently a family of six distinct insulin-like growth factor binding proteins (IGFBPs) have been identified and the gene structures of the first five (IGFBP-1, -2, -3, -4 and -5) characterized. We now isolated the IGFBP-6 gene from a rat genomic library and determined its organization as well as the DNA sequence at the 5' flanking region of the gene. The rat IGFBP-6 gene spans 5.1 kb of the genomic sequence and contains four exons interrupted by three introns of approximately 2.4, 0.2 and 1.2 kb in length, respectively. Primer extension analysis and ribonuclease protection assay using RNA from rat lung tissues demonstrated two transcriptional start sites located at 85 and 82 nucleotides upstream of the ATG translational initiation codon. The promoter region of the rat IGFBP-6 gene is devoid of a TATA or a CAAT consensus sequence motif, but putative regulatory cis elements, including a Sp1, an estrogen receptor binding site and a retinoic acid responsive element, are present in the promoter region.

Insulin-like growth factor binding protein-4, -5 and -6 mRNAs in the human fetus: localization to sites of growth and differentiation?

The insulin-like growth factor binding proteins (IGFBP) modulate the regulatory actions of insulin-like growth factors (IGF) on fetal growth and development. We have determined the sites of IGFBP-4, -5 and -6 synthesis in 14-18 weeks gestation human fetal tissues using northern blot analysis and in situ hybridization to localize their mRNAs. IGFBP-4, -5 and -6 mRNAs were present in most fetal tissues at this gestational age. IGFBP-4 mRNA (2.3 kb) was widely expressed, most abundantly in kidney, stomach, intestine and lung and least in the liver. IGFBP-5 mRNA (6 kb) was in highest abundance in muscle, skin, stomach and intestine. IGFBP-6 mRNA (1.4 kb) was expressed with greatest abundance in the heart, muscle and skin and least in the liver. In situ hybridization confirmed the widespread occurrence of these mRNAs. The distribution of all three IGFBP mRNAs was similar in each tissue with variations in relative abundance between different regions. In general, IGFBP-4, -5 and -6 mRNAs were prevalent in regions of active cellular division and differentiation, suggesting that the binding proteins they encode specify the sites of IGF activity in the developing fetus. The widespread occurrence of their mRNAs suggests that, like IGFs, they are synthesized in multiple tissues in the fetus and have an autocrine or paracrine mode of action.

Structural and functional characterization of the rat follistatin (activin-binding protein) gene promoter

Follistatin was originally identified as a specific inhibitor of follicle stimulating hormone secretion and later characterized as a binding protein for activin. Since activin regulates hormone secretion and cell differentiation, the importance of understanding the mechanisms regulating the synthesis of its binding protein, follistatin, is evident. To study the regulation of follistatin gene expression, we first determined the transcription start site (cap site) of the rat follistatin gene using primer extension and ribonuclease protection assay. Our results led to the identification of multiple cap sites located at three different positions of the promoter. DNA sequence analysis revealed that each cap site was located at approximately 30 nucleotide (nt) downstream of three distinct TATA-like sequences. In primary cultures of rat granulosa cells, transfection studies using 5'-flanking regions of follistatin gene fused to the chloramphenicol acetyltransferase (CAT) reporter gene revealed the presence of two DNA segments that act to suppress basal transcriptional activity. The promoter activity of the CAT construct containing 2.6 kilo base pairs (kb) of 5'-flanking region was induced 2.5-fold above basal activity by forskolin (10 microM), and 1.6-fold by 12-O-tetradecanoylphorbol 13-acetate (TPA, 100 nM). Co-treatment with forskolin and TPA resulted in a 6.4-fold induction in its promoter activity, suggesting that two distinct signal transduction pathways, the cAMP-dependent protein kinase-A pathway and diacylglycerol-dependent protein kinase-C pathway, act coordinately to modulate follistatin gene transcription. Experiments using a series of 5'-flanking region deletion constructs located the regulatory regions responsive to these two pharmacological agents at nt -312 to -32 and -35 to +139.

Development of specific antibodies to rat insulin-like growth factor-binding proteins (IGFBP-2 to -6): analysis of IGFBP production by rat granulosa cells

Six insulin-like growth factor-binding proteins (IGFBPs) have been isolated and their cDNAs cloned in the rat and human species. The next step is to develop antibodies to each IGFBP. Toward this goal, we generated rabbit polyclonal antibodies to rat IGFBP-2, -4, -5, and -6, using synthetic peptide fragments of the IGFBPs. A rat IGFBP-3 polyclonal antibody was prepared in a previous study using the native protein. Western immunoblotting demonstrated that the IGFBP-2, -3, -4, -5, and -6 antibodies were highly specific for their respective antigens. The elicited antisera were used to study IGFBP production in primary cultures of rat granulosa cells grown in serum-free medium for 72 h. Ligand blotting with 125I-labeled IGF-I and IGF-II revealed two bands migrating at 29 and 24 kilodaltons (kDa) in the medium of untreated control cells, whereas no bands were detectable in medium from cells incubated with 100 ng/ml FSH. Western blotting of control medium with all of the IGFBP antibodies revealed that the IGFBP-4 antibody stained two bands at 28 and 24 kDa, and the IGFBP-5 antibody stained two bands at 30 and 29 kDa. By contrast, these bands were absent in medium from FSH-stimulated cells; instead, two lower molecular mass bands of 21.5 and 17.5 kDa were detected with the IGFBP-4 antibody, and a 21-kDa band was seen with the IGFBP-5 antibody. The same 21.5- and 17.5-kDa bands were seen when exogenously added IGFBP-4 was incubated with the FSH-conditioned medium, whereas untreated medium did not degrade the added IGFBP-4. Incubation with the conditioned medium also degraded exogenous IGFBP-5 to yield a 21-kDa band. By contrast, medium from control cells did not degrade the exogenous IGFBP-5. This finding indicates that FSH induced the production of a protease from granulosa cells that degraded IGFBP-4 and -5 in the culture medium. No IGFBPs were detectable in medium from control or FSH-treated cells using the IGFBP-2, -3, and -6 antibodies. Northern blotting analysis of the same control granulosa cell cultures revealed a 2.6-kilobase and a 6.0-kilobase transcript for IGFBP-4 and -5, respectively; however, the IGFBP-4 and -5 mRNAs were essentially undetectable in FSH-treated cell cultures. To determine the effects of the IGFBPs on steroidogenesis, dose-response experiments were performed with IGFBP-4 and -5.(ABSTRACT TRUNCATED AT 400 WORDS)

Structure of the rat insulin-like growth factor binding protein-4 gene

A family of six distinct insulin-like growth factor binding proteins (IGFBPs) have been isolated and their cDNA sequences characterized from rat and human species. Recently, the gene structures of the first three IGFBPs (IGFBP-1, -2 and -3) have also been determined. We now report the isolation of the rat IGFBP-4 gene and its genomic organization, as well as the DNA sequence of the promoter region. Rat IGFBP-4 gene spans at least 12 kilobases (kb) of the genomic sequence. It consists of four exons separated by three introns with approximate size of 6.4, 0.6 and 2.7 kb. A single transcriptional start site is located at 249 nucleotides upstream of the translational initiation ATG codon. The rat IGFBP-4 gene possesses a typical TATA box and a CAAT box, as well as multiple potential cis elements, including three cAMP responsive elements, three AP-1 binding sites and one progesterone receptor binding site in the 5' flanking region. The presence of these potential cis elements supports the tissue-specific expression of the IGFBP-4 gene.

Cloning of the rat insulin- like growth factor binding protein-5 gene and DNA sequence analysis of its promoter region

To understand the regulation of the insulin-like growth factor binding protein-5 (IGFBP-5) gene expression, we have cloned the IGFBP-5 gene from rat genomic libraries and determined its genomic organization as well as the DNA sequence at the 5' flanking region of the gene. The rat IGFBP-5 gene spans at least 17 kilobases (kb) of the genome and contains 4 exons interrupted by 3 introns of approximately 10, 0.6 and 0.7 kb, respectively. Southern blot analysis of the rat chromosome DNA revealed a single copy gene for IGFBP-5 in the haploid genome. Primer extension experiments demonstrated a single transcriptional start site located at 772 nucleotides 5' of the ATG translational start codon. In addition to a TATA box and a CAAT box, multiple putative cis-regulatory elements, including an AP-1, an AP-2 and a binding site for progesterone receptor are present in the promoter region. This finding suggests that the IGFBP-5 gene is one of those that are expressed in a tissue-specific manner.

Regulation of insulin-like growth factor binding proteins in ovarian cancer cells by oestrogen

Insulin-like growth factor-I (IGF-I), its receptor and its binding proteins are expressed by ovarian cancer cells. In this study, we examined oestradiol (E2) regulation of IGF-I and IGF binding proteins (IGFBP) in an oestrogen-responsive ovarian cancer cell line, PE04. In serum-free conditions, PE04 cell monolayer growth was increased 1.64-fold by 3 nmol/l E2 compared with controls, although IGF-I mRNA levels were not increased. In contrast to IGF-I mRNA, IGFBP mRNA was regulated by E2. E2 caused a marked decrease in IGFBP-3 RNA, but IGFBP-2, -4 and -6 levels were only minimally depressed. IGFBP-5 mRNA levels were increased by E2. Tamoxifen had less effect on IGFBP mRNA regulation. Ligand blotting showed that E2 reduced IGFBP levels in conditioned media. IGFBP RNA was also detected in human ovarian tissue samples. Thus, IGFBP expression can be regulated in oestrogen-responsive ovarian cancer by E2.

Localization of the heparin binding site of follistatin

To define the heparin-binding site of follistatin, the reduced and S-carboxymethylated recombinant human follistatin containing 288 amino acids was digested by Staphylococcus aureus V8. The digested product was subjected to sulfate cellufine column chromatography and the adsorbed peptide fragments eluted with a stepwise gradient of sodium chloride. The recovered column fractions were further purified by reversed-phase high-performance liquid chromatography (HPLC) and the HPLC peaks subjected to amino-terminal sequence analysis. All of the sulfate cellufine-retarded peptide fragments gave the same N-terminal amino acid sequence, which started at residue-68 of human follistatin, suggested that those fragments starting from residue-68 contain the heparin binding site. The multiple fragments might represent the oxidized, non-glycosylated or glycosylated forms of follistatin(68-113) resulting from the V8 digestion. A synthetic peptide corresponding to the region having the amino acid sequence 72-86 of follistatin was able to bind both heparin and sulfate cellufine, as well as compete with recombinant follistatin for binding to heparin. These findings further define the location of the heparin and heparan sulfate-binding site of follistatin at the basic amino acid-rich region comprising the amino acid sequence Lys75-Lys-Cys-Arg-Met-Asn-Lys-Lys-Asn-Lys-Pro-Arg86.

Expression of inhibin beta A and beta B, follistatin and activin-A receptor messenger ribonucleic acids in the rat seminiferous epithelium

The expression of inhibin beta A and beta B subunits, follistatin, and activin-A receptor messenger RNA (mRNAs) in different stages of rat seminiferous epithelial cycle was analyzed by in situ hybridization in order to understand their role in the regulation of spermatogenesis. Inhibin beta A mRNA was expressed in Sertoli cells in a highly stage-specific manner. The mRNA levels started to accumulate in Sertoli cells at stage VIII of the cycle and were highly expressed during stages IX-XI. Follistatin mRNA expression was identical to that of inhibin beta A, while inhibin beta B mRNA was maximally expressed in Sertoli cells at stages XIII-III. Low expression was found in stages VII-VIII. Activin-A receptor mRNA was localized mainly in spermatogenic cells. Maximal expression was seen in late primary spermatocytes at stages XIII-XIV and in early round spermatids at stages I-IV. A low even expression by Sertoli cells was also seen. Inhibin beta A and follistatin mRNAs were coexpressed in stage IX-XI Sertoli cells, suggesting close interplay between these molecules. The pattern of inhibin beta B mRNA expression was similar to that of inhibin alpha-mRNA. Localization of activin-A receptor mRNA in spermatogenic cells suggests that activin may influence meiotic divisions and early spermiogenesis.

Regulation of insulin-like growth factor-binding protein (IGFBP) expression by breast cancer cells: use of IGFBP-1 as an inhibitor of insulin-like growth factor action

BACKGROUND

The insulin-like growth factors (IGFs) play an important role in normal growth and development. Evidence suggests they may also regulate the growth of several cancer cell types. This regulation is mediated by interactions between the receptors and ligands. There is now ample evidence to suggest that these interactions are also influenced by extracellular IGF-binding proteins (IGFBPs). Six different IGFBPs have been cloned. Some species may act to inhibit the mitogenic effects of the IGFs. Since breast cancer cells are responsive to the IGFs, it is possible that regulated expression of the IGFBPs affects tumor growth. Furthermore, inhibitory binding proteins could be used as neutralizers of IGF action.

PURPOSE

We conducted this study to fully characterize the expression and hormonal regulation of IGF-binding protein expression in human MCF-7 breast cancer cells and to test the ability of purified IGFBP-1 to inhibit IGF-I action.

METHODS

We used ribonuclease protection assays and Western ligand blotting to examine IGFBP expression in MCF-7 cells. The effect of IGF-I, IGFBP-1, and 17 beta-estradiol on serum-free cell growth was also studied.

RESULTS

MCF-7 cells expressed IGFBP-2, IGFBP-4, and IGFBP-5 RNA and protein. These cells are dependent on estrogen for growth. In short-term culture, IGF-I can substitute for estrogen. Concomitant addition of IGF-I and estrogen enhanced stimulation above the level achieved by either factor alone. Estrogen also increased IGFBP production, making it unlikely that the IGFBPs induced by estrogen in MCF-7 cells could function as major inhibitors of IGF action. In contrast, exogenous addition of IGFBP-1 could block IGF-I-induced mitogenesis; this effect was reversible by excess IGF-I.

CONCLUSIONS

The studies suggest that cancer cell growth may be regulated by endogenous IGFBP expression. Furthermore, the exogenous addition of the IGFBP-1 blocked IGF-I action and potentially could be used as a pharmacologic inhibitor of IGF action.

Sweet's syndrome associated with subacute necrotizing lymphadenitis

A 34-year-old man with Sweet's syndrome associated with subacute necrotizing lymphadenitis is reported. Histological examination of an erythematous, painful, cutaneous plaque revealed a dermal interstitial neutrophilic infiltrate. A biopsy specimen obtained from an inguinal lymph node showed granulomatous formation, consisting of histiocytes, with central necrosis in the paracortex and macrophages in the sinus. Although the causes of the two diseases remain obscure, this appears to be the first report of Sweet's syndrome associated with subacute necrotizing lymphadenitis.

Expression of insulin-like growth factor-binding protein-2 and -3 messenger ribonucleic acid in the porcine ovary: localization and physiological changes

Insulin-like growth factor-binding protein (IGFBP)-2 and -3 are the most prevalent IGFBPs in porcine follicular fluid, as determined on ligand blots, but little is known about the localization and regulation of their synthesis in vivo. This study was designed to investigate the localization and cyclic regulation of the mRNA for these two IGFBPs in the porcine ovary, RNA was extracted from whole ovaries morphologically classified as immature, preovulatory, and luteal. Northern hybridization analysis of this RNA showed no significant difference in the expression of IGFBP-2 mRNA in these ovaries (OD for preovulatory, luteal, and immature ovaries, 0.076 +/- 0.01, 0.071 +/- 0.01, and 0.10 +/- 0.008/micrograms RNA, respectively). IGFBP-3 mRNA was not different in immature and preovulatory ovaries, but was 10-fold greater (P less than 0.025) in luteal ovaries. Northern analysis of RNA extracted from ovaries also showed no significant change in IGFBP-2 mRNA on days (d) 11, 16, and 21 of the estrous cycle. IGFBP-3 mRNA tended to decrease between d11-16 with the onset of luteal regression and was significantly decreased in d21 preovulatory ovaries to 22% of the values in d11 ovaries. Granulosa, thecal, and luteal cells were also analyzed for IGFBP mRNA. IGFBP-2 mRNA was most abundant in granulosa cells, lower in thecal cells, and lowest in luteal cells. No IGFBP-3 mRNA could be detected in granulosa cells, and luteal cells expressed 15- to 63-fold greater levels than thecal cells. These results show that IGFBP-2 and -3 mRNAs are expressed in specific ovarian cell types and that their expression appears to be independently regulated during the reproductive cycle. This provides further evidence for the importance of these proteins as paracrine/autocrine regulators of ovarian function.

Gonadotropin and cAMP modulation of IGE binding protein production in ovarian granulosa cells

Porcine granulosa cells (GC) produce insulin-like growth factor (IGF) binding protein (BP)-3 and IGFBP-2 in culture. A gonadotropin, follicle-stimulating hormone (FSH), dramatically inhibited GC production of these IGFBPs in control cultures and in cultures stimulated by insulin plus epidermal growth factor (EGF) or IGF-I plus EGF. Stimulators of adenylate cyclase (forskolin, cholera toxin) and a derivative of adenosine 3',5'-cyclic monophosphate (cAMP), 8-bromoadenosine 3',5'-cyclic monophosphate, inhibited IGFBP synthesis in a manner similar to FSH. In contrast, the antagonist of cAMP action, (R)-p-adenosine 3',5'-cyclic phosphorothioate [(R)-p-cAMPS], significantly stimulated production of IGFBP-3 and IGFBP-2 compared with controls. This stimulatory effect of (R)-p-cAMPS was counteracted by cotreatment with FSH in a dose-dependent manner. Finally, treatment of GC cultures with FSH plus 3-isobutyl-1-methylxanthine resulted in a significant reduction in cellular content of mRNA coding for IGFBP-3 with no change in IGFBP-2 mRNA. In summary, agents that elevate intracellular cAMP were found to mimic the effects of FSH on IGFBP production.